HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Factor IX Deventer-evidence for the heterogeneity of hemophilia BM.

Abstract
Factor IX Deventer was isolated from the plasma of a patient with severe hemophilia B. The patient was classified as BM because of an abnormal prolongation (2.1 times) of the ox-brain prothrombin time, that could be corrected by addition of antifactor IX serum. Experiments with the isolated factor IX Deventer showed that one of the two peptide bonds involved in the proteolytic activation of factor IX cannot be cleaved by physiological or non-physiological activators (XIa and RVV-X, respectively). Such a defect can explain why the molecule has no procoagulant activity. At present it is not clear why this defect makes factor IX Deventer such an effective inhibitor of the ox-brain prothrombin time. It is proposed that hemophilia BM is a heterogeneous disorder.
AuthorsR M Bertina, I K van der Linden
JournalThrombosis and haemostasis (Thromb Haemost) Vol. 47 Issue 2 Pg. 136-40 (Apr 30 1982) ISSN: 0340-6245 [Print] Germany
PMID7101232 (Publication Type: Journal Article)
Chemical References
  • Factor IX
Topics
  • Factor IX (isolation & purification, metabolism, pharmacology)
  • Hemophilia B (blood, genetics)
  • Humans
  • Prothrombin Time

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: